Research programme: anti-RSV monoclonal antibodies - Medarex/MedImmune

Drug Profile

Research programme: anti-RSV monoclonal antibodies - Medarex/MedImmune

Alternative Names: Anti-RSV monoclonal antibodies research programme - Medarex/MedImmune

Latest Information Update: 21 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 31 Dec 2005 No development reported - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)
  • 29 Sep 2004 This programme is still in active development
  • 27 Jul 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top